JP2015535291A - 腎臓に障害のある対象におけるポマリドミドを用いる癌の治療 - Google Patents

腎臓に障害のある対象におけるポマリドミドを用いる癌の治療 Download PDF

Info

Publication number
JP2015535291A
JP2015535291A JP2015540844A JP2015540844A JP2015535291A JP 2015535291 A JP2015535291 A JP 2015535291A JP 2015540844 A JP2015540844 A JP 2015540844A JP 2015540844 A JP2015540844 A JP 2015540844A JP 2015535291 A JP2015535291 A JP 2015535291A
Authority
JP
Japan
Prior art keywords
cancer
pomalidomide
dexamethasone
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015540844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535291A5 (enExample
Inventor
イブ カッセッラ クラウディア
イブ カッセッラ クラウディア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2015535291A publication Critical patent/JP2015535291A/ja
Publication of JP2015535291A5 publication Critical patent/JP2015535291A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015540844A 2012-11-05 2013-11-04 腎臓に障害のある対象におけるポマリドミドを用いる癌の治療 Pending JP2015535291A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261722722P 2012-11-05 2012-11-05
US61/722,722 2012-11-05
US201361764466P 2013-02-13 2013-02-13
US61/764,466 2013-02-13
PCT/US2013/068237 WO2014071280A1 (en) 2012-11-05 2013-11-04 Treatment of cancer with pomalidomide in a renally impaired subject

Publications (2)

Publication Number Publication Date
JP2015535291A true JP2015535291A (ja) 2015-12-10
JP2015535291A5 JP2015535291A5 (enExample) 2016-12-28

Family

ID=50628132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015540844A Pending JP2015535291A (ja) 2012-11-05 2013-11-04 腎臓に障害のある対象におけるポマリドミドを用いる癌の治療

Country Status (15)

Country Link
US (1) US20150297579A1 (enExample)
EP (1) EP2914112A4 (enExample)
JP (1) JP2015535291A (enExample)
CN (1) CN104902754A (enExample)
AU (1) AU2013337352A1 (enExample)
BR (1) BR112015010039A2 (enExample)
CA (1) CA2889987A1 (enExample)
EA (1) EA201590883A1 (enExample)
HK (1) HK1214552A1 (enExample)
IL (1) IL238563A0 (enExample)
MX (1) MX2015005548A (enExample)
NI (1) NI201500063A (enExample)
PH (1) PH12015501002A1 (enExample)
SG (1) SG11201503456TA (enExample)
WO (1) WO2014071280A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511485A (ja) * 2016-03-02 2019-04-25 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー アミノベンゾイミダゾール誘導体
JP2020533316A (ja) * 2017-09-06 2020-11-19 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー アミノベンゾイミダゾール誘導体、治療、およびヒストン脱アセチル化酵素を阻害する方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507759WA (en) * 2013-04-02 2015-10-29 Celgene Corp Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
EP3297674B1 (en) * 2015-05-22 2023-01-04 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
CN105456232A (zh) * 2015-09-08 2016-04-06 刘剑 一种泊马度胺速溶膜剂及其制备方法
WO2018013689A1 (en) * 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
CN108721304B (zh) * 2017-04-17 2020-10-16 北京大学 用于治疗肿瘤的药物组合物及其用途
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
GB202012160D0 (en) * 2020-08-05 2020-09-16 Vicore Pharma Ab New compositions
EP4479082A2 (en) * 2022-02-15 2024-12-25 The Broad Institute, Inc. Cell-type specific targeting contractile injection system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010111650A (ja) * 2008-11-10 2010-05-20 Niigata Univ サリドマイドまたはその誘導体を有効成分とする統合失調症の治療薬
WO2011125911A1 (ja) * 2010-03-31 2011-10-13 国立大学法人金沢大学 金属錯体およびこれを有効成分として含有する抗がん剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP2014517915A (ja) * 2011-04-18 2014-07-24 セルジーン コーポレイション 多発性骨髄腫治療のためのバイオマーカー
EP3096142A3 (en) * 2011-04-29 2017-03-08 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010111650A (ja) * 2008-11-10 2010-05-20 Niigata Univ サリドマイドまたはその誘導体を有効成分とする統合失調症の治療薬
WO2011125911A1 (ja) * 2010-03-31 2011-10-13 国立大学法人金沢大学 金属錯体およびこれを有効成分として含有する抗がん剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIMOPOULOS, MELETIOS, A, ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 28, JPN6017046790, 18 October 2010 (2010-10-18), pages 4976 - 84, ISSN: 0003907261 *
RICHARDSON, P.G., ET AL., BLOOD, vol. 121, JPN6017046787, 14 December 2012 (2012-12-14), pages 1961 - 7, ISSN: 0003907259 *
吉村学、西村眞人, 日本臨床, vol. 53, JPN6017046792, 1995, pages 464 - 8, ISSN: 0003907260 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511485A (ja) * 2016-03-02 2019-04-25 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー アミノベンゾイミダゾール誘導体
JP2020533316A (ja) * 2017-09-06 2020-11-19 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー アミノベンゾイミダゾール誘導体、治療、およびヒストン脱アセチル化酵素を阻害する方法
US11780816B2 (en) 2017-09-06 2023-10-10 Translational Drug Development, Llc Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase

Also Published As

Publication number Publication date
PH12015501002A1 (en) 2015-07-27
HK1214552A1 (zh) 2016-07-29
SG11201503456TA (en) 2015-05-28
WO2014071280A1 (en) 2014-05-08
EA201590883A1 (ru) 2015-09-30
BR112015010039A2 (pt) 2017-07-11
US20150297579A1 (en) 2015-10-22
CA2889987A1 (en) 2014-05-08
EP2914112A4 (en) 2016-06-15
AU2013337352A1 (en) 2015-05-21
CN104902754A (zh) 2015-09-09
IL238563A0 (en) 2015-06-30
NI201500063A (es) 2015-09-10
MX2015005548A (es) 2016-01-15
EP2914112A1 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
JP2015535291A (ja) 腎臓に障害のある対象におけるポマリドミドを用いる癌の治療
CN109069512B (zh) 取代的氨基嘌呤化合物、其组合物以及相关治疗方法
CN101583359B (zh) 3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮在套细胞淋巴瘤治疗中的用途
KR100790589B1 (ko) 암 치료용 조성물 및 치료 방법
AU2018360766B2 (en) Anticancer agents
KR102272274B1 (ko) (ｓ)-3-(4-((4-(모르폴리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온의 제제
JP6162709B2 (ja) シチジンアナログの経口製剤を使用して癌を治療する方法
JP7357637B2 (ja) ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの同位体置換体
BRPI0616670A2 (pt) uso de 3-(4-amino-1-oxo-1,3-diidro-isoindol-2-il)-piperidina-2,6- diona, e, uso do mesmo e de um agente ativo secundário
EP3166635A1 (en) Combination therapy for cancer
EA037508B1 (ru) Композиции 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида
JP6469077B2 (ja) ４−アミノ−２−（２，６−ジオキソ−ピペリジン３−イル）−イソインドリン−１，３−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物
JP2018518509A (ja) 白金化合物、組成物及びその使用
JP7547360B2 (ja) Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
KR20180088401A (ko) 3-(5-아미노-2-메틸-4-옥소-4h-퀴나졸린-3-일)-피페리딘-2,6-다이온을 사용한 주기 요법
WO2016164336A1 (en) Hepatocellular carcinoma treatment using a combination of cc 122 and sorafenib
KR20150081450A (ko) 신장 장애 대상체에서 포말리도마이드(pomalidomide)를 이용한 암의 치료
HK1125856A (en) Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
BR122024004327A2 (pt) Combinação, composição farmacêutica, kit, composto, uso de um inibidor da histona desacetilase (inibidor de hdac) e uso de um composto

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181030